Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06951932
NA

Evaluation of the Impact of Medium-chain Fatty Acids in the Evolution of Newly Diagnosed Mild Cognitive Impairment

Sponsor: Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria

View on ClinicalTrials.gov

Summary

Mild cognitive impairment (MCI) is considered the intermediate stage between the changes observed in physiological aging and dementia. Currently, there is no drug therapy, and available drugs offer only minimal benefit on symptoms, only partially slowing the course of the condition. Studies in the literature have investigated the role of omega-3 fatty acids in MCI, and when administered over a period of six months, they appear to improve clinical condition and mood. In addition, medium-chain triglycerides (MCTs) appear to exert an antioxidant function, enhance cognitive ability in patients with MCI or Alzheimer's, and promote deep sleep state.

Official title: Evaluation of the Impact of Medium-chain Fatty Acids in the Evolution of Newly Diagnosed Mild Cognitive Impairment: Prospective Randomized Controlled Trial

Key Details

Gender

All

Age Range

18 Years - 85 Years

Study Type

INTERVENTIONAL

Enrollment

120

Start Date

2024-07-03

Completion Date

2025-11-03

Last Updated

2025-05-04

Healthy Volunteers

No

Interventions

DIETARY_SUPPLEMENT

Mediterranean-type diet with MCT supplementation

The treatment arm will follow a Mediterranean diet supplemented by daily intake of MCT (30 mL)

OTHER

Mediterranean-type food regimen using extra virgin olive oil

The arm will follow a Mediterranean diet with an indication to take extra virgin olive oil as the main fat in the diet daily

Locations (1)

Clinical Trial Center

Alessandria, Piedmont, Italy